Ottawa, ON – Today, the Alliance for Safe Biologic Medicines (ASBM) released results from a survey that found that Canadian physicians overwhelmingly support Health Canada implementation of distinguishable names. Survey results also found that Canadian physicians are open to substituting biosimilars for non-medical reasons, only when they are the ultimate decision-maker for their patient, not […]
On September 10, 2017 ASBM presented a poster at the European Society of Medical Oncology (ESMO) 2017 Congress which presented perspectives of oncologists from 12 countries regarding biosimilar substitution. Responses were drawn from five recent ASBM surveys which gathered perspectives of more than 1,850 biologic prescribers in Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the […]
On July 28th, 2017 the Australian Therapeutic Goods Administration (TGA) announced that it was seeking comments from interested parties on the nomenclature for biologic medicines, including biosimilars. In a comment letter dated September 7th, ASBM responded, advocating for distinct naming of all biologics and biosimilars, and urging the TGA to adopt the World Health Organization’s […]
